ClinicalTrials.Veeva

Menu

Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy

U

University General Hospital of Heraklion

Status

Enrolling

Conditions

Osteoporosis

Treatments

Drug: Anti-osteoporotic medication( alendronate or denosumab)

Study type

Observational

Funder types

Other

Identifiers

NCT04861142
3224 (Other Identifier)

Details and patient eligibility

About

Osteoporosis and osteoporotic fractures, especially hip fractures, have a significant impact on public healthcare. Despite the fact that the patients that have suffered an osteoporotic fracture have 86% increased risk of sustaining a second osteoporotic fracture, the efforts to prevent these fractures remain inadequate. The in-hospital initiation of antiosteoporotic treatment in patients that have been admitted due to hip fracture has shown to improve treatment rates and contribute to second fracture prevention. For this purpose the Arbeitsgemeinschaft für Osteosynthesefragen (AO) Foundation has introduced an algorithm that can be used by Orthopedic surgeons for the prevention of second fracture in patients that have already suffered an osteoporotic fracture. The purpose of this thesis is to study the efficacy of this algorithm in preventing the second fracture in the greek population. The study will include patients that have been admitted in the Orthopedics department of the University Hospital of Heraklion due to hip fracture. Bone density measurement will be performed using the DXA method and antiosteoporotic treatment will be administered according to the algorithm. These patients will be included in the hip registry of the Orthopedics department and the follow-up will last for 2 years .The primary aims of the study are: a)evaluation of the adherence to the antiosteoporotic medication b)the efficacy of the adherence to the aforementioned clinical algorithm in the secondary fracture prevention in the greek population.

Enrollment

350 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with hip fractures after low-energy falls(fragility fractures)

Exclusion criteria

-Patients with hip fractures after high energy falls

Trial design

350 participants in 2 patient groups

Patients adherent to the anti-osteoporotic medication
Treatment:
Drug: Anti-osteoporotic medication( alendronate or denosumab)
Patients non-adherent to the anti-osteoporotic medication
Treatment:
Drug: Anti-osteoporotic medication( alendronate or denosumab)

Trial contacts and locations

1

Loading...

Central trial contact

Theodoros Tosounidis, Assistant Professor; Ioannis Daskalakis, Orthopaedic Surgery Resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems